Letter to the Editor: Insight into the nonlinear association between thyroid-stimulating hormone and suicide risk in first-episode major depressive disorder

Abstract

The relationship between the hypothalamic-pituitary-thyroid (HPT) axis and suicidal behavior in major depressive disorder (MDD) has been a subject of clinical debate for some time. The study by Deng et al published in the recent issue of the World Journal of Psychiatry, present a comprehensive analysis of 1718 Chinese patients with first-episode drug-naïve MDD, identifying a substantial nonlinear relationship between serum thyroid-stimulating hormone (TSH) levels and suicide attempts (SAs). The study identifies a critical inflection point at 5.43 μIU/mL, beyond which each unit increase in TSH correlates with a 21% increase in SA risk. While these findings offer a promising biomarker, they also invite a deeper discussion regarding sexual dimorphism and the metabolic-endocrine nexus. Specifically, the higher prevalence of thyroid dysfunction in women necessitates a more granular, sex-stratified approach to data analysis. Furthermore, the interplay between TSH, lipid metabolism, and glucose regulation-all of which have been independently linked to suicidality-deserves investigation as a unified biosignature. This letter explores the neurobiological mechanisms linking the HPT axis to self-harm, the necessity of sex-sensitive risk thresholds, and the importance of metabolic screening in suicide prevention.

Key Words: Major depressive disorder; Thyroid-stimulating hormone; Suicide attempts; Sex differences; Metabolic markers; First-episode drug-naïve

Core Tip: Deng et al identify a TSH threshold of 5.43 μIU/mL as a significant predictor of suicide attempts in first-episode drug-naïve-major depressive disorder (MDD) patients. However, to translate these findings into clinical practice, researchers must account for the biological reality that hypothyroidism and MDD phenotypes differ significantly by sex. Additionally, the relationship between thyroid-stimulating hormone and suicide should be interpreted within the broader context of metabolic health, as thyroid function and lipid/glucose metabolism are physiologically intertwined and collectively influence neurobiological vulnerability to self-harm.

TO THE EDITOR

Deng et al[1] published in the recent issue of the World Journal of Psychiatry, provided substantial evidence in support of their hypothesis. To that end, the authors conducted a study that utilized a large, homogeneous sample of 1718 first-episode drug-naïve (FEDN)-major depressive disorder (MDD) patients. From a methodological perspective, the emphasis on drug-naïve patients constitutes a significant strength, as it eliminates the complex confounding effects of antidepressants. Medications such as selective serotonin reuptake inhibitors and tricyclic antidepressants have been demonstrated to significantly modulate thyroid-stimulating hormone (TSH) levels and peripheral thyroid metabolism, frequently obscuring the baseline endocrine state of the patient[2]. By synthesizing recent findings on the gut-brain-thyroid axis and metabolic shunts, this commentary provides a novel conceptual framework that moves beyond viewing TSH as an isolated marker. Our goal is to bridge the gap between endocrine monitoring and psychiatric crisis intervention by identifying specific metabolic-endocrine signatures that define high-risk clinical subtypes.

The identification of a nonlinear relationship, characterized by the discernment of an inflection point at 5.43 μIU/mL, signifies a notable progression beyond the limitations of conventional linear models. The authors provide a practical clinical “red flag” by demonstrating that risk only escalates significantly once TSH crosses into the mildly pathologically elevated range. However, the study’s single-center design and exclusive focus on the Han Chinese population may limit the generalizability of this specific numerical threshold. The inflection point may be subject to shifts due to variations in dietary iodine intake and genetic predispositions for autoimmune thyroiditis across different ethnic groups. Additionally, the cross-sectional nature of the data captures TSH at a single point in time, whereas suicide attempts were recorded as a lifetime history. This methodological limitation precludes the ability to draw definitive conclusions regarding the temporal causality of the relationship between TSH elevation and the onset of suicidal behavior.

Neurobiological intersection of hypothalamic-pituitary-thyroid axis dysfunction and suicidal behavior

The correlation between thyroid irregularities-specifically elevated TSH and diminished hormone levels-and suicide attempts indicates a significant disruption in the hypothalamic-pituitary-thyroid (HPT) axis that extends far beyond simple peripheral thyroid hormone deficiency[3]. This association in depressed patients is primarily driven by a systemic breakdown of the HPT axis, which can culminate in a localized state known as “brain hypothyroidism”[4]. Even in instances of subclinical hypothyroidism, where TSH levels are elevated while free triiodothyronine and free thyroxine remain within the normal range, the brain may undergo this “local” deficiency. In a typical physiological stress response, the body endeavors to mitigate low serotonin levels by augmenting HPT axis activity to enhance thyroid hormone production. However, in individuals with suicidal tendencies, this compensatory mechanism appears to be severely impaired. Despite peripheral blood tests initially appearing normal, these patients frequently manifest “low T3 syndrome”, a state where the brain exhibits an inability to convert thyroxine (T4) into the active triiodothyronine (T3)[5].

This conversion process is often impeded by hypercortisolemia resulting from chronic stress in MDD. Elevated cortisol levels hinder the crucial deiodinase enzymes required for T4-to-T3 conversion, illustrating the close interaction between the HPT axis and the hypothalamic-pituitary-adrenal axis[5,6]. Thyroid hormones are critical for neuroplasticity, myelination, and the modulation of several neurotransmitter systems, most notably the serotonergic system, where T3 serves as a vital co-regulator of 5-HT neurotransmission[7,8]. Consequently, an internal thyroid deficiency induces a state of destabilization within this system. While an increase in TSH represents a compensatory response to maintain homeostasis, the resulting endocrine strain leads to a decrease in 5-HT1A receptor sensitivity in the prefrontal cortex-a region essential for the top-down inhibition of impulsive actions[3,9].

Specifically, low thyroid levels result in increased sensitivity in 5-HT2 receptors and reduced sensitivity in 5-HT1A autoreceptors, a combination strongly linked to the pathogenesis of suicidal behavior[10]. Because low serotonergic activity is the most consistent biological finding in individuals who have committed suicide, the elevated TSH observed in clinical studies likely reflects a state of diminished neurochemical resilience[9]. Beyond neurotransmitters, hypothyroidism-induced cerebral energy metabolism impairment is a salient phenomenon; it leads to a reduction in glucose consumption and a disruption in oxidative phosphorylation within the hippocampus and frontal cortex. This effectively starves the brain of the energy necessary for maintaining cognitive stability and emotional regulation[10].

Furthermore, markers of HPT dysfunction, such as a blunted TSH response to thyrotropin-releasing hormone (TRH), serve as physiological indicators of increased risk for violent suicide attempts[11]. Under normal conditions, TSH acts as a buffer, but elevated TSH or a failed TRH response can indicate a failure of the body’s natural stress-buffering mechanisms, leaving the individual more vulnerable to overwhelming psychological pain (Figure 1)[6]. Genetic factors, including variants that repress serotonin receptor expression and the presence of thyroid antibodies like thyroid peroxidase antibodies (TPOAb), further exacerbate this risk[11]. Ultimately, the brain enters a state of treatment resistance characterized by a deficiency in hormonal support essential for neuroprotection, resulting in a marked exacerbation of suicidal ideation and behavior (Table 1).

Figure 1 The neurobiological interface of the hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes in major depressive disorder-related suicidality. This conceptual diagram illustrates the complex physiological cross-talk driving suicidal vulnerability. Chronic stress (central) activates the hypothalamic-pituitary-adrenal axis, resulting in hypercortisolemia. Concurrently, it disrupts the hypothalamic-pituitary-thyroid axis by inhibiting deiodinase enzymes. This prevents the essential conversion of thyroxine to triiodothyronine within the brain, leading to localized “brain hypothyroidism.” This deficiency destabilizes the serotonergic system, reducing impulse control. Elevated TSH represents an insufficient compensatory feedback response. HPT-HPA: Hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal; CRH: Corticotropin-releasing hormone; ACTH: Adrenocorticotropic hormone; TSH: Thyroid-stimulating hormone.

Table 1 Hypothalamic-pituitary-thyroid axis dysregulation and suicidal pathogenesis.

Biological marker	Neurobiological impact	Contribution to suicidal behavior
Elevated TSH	Reflects “local” brain hypothyroidism and compensatory endocrine strain	Indicates diminished neurochemical resilience and failure of stress-buffering[3,7,9]
Low T3 (active)	Impairs conversion from T4; reduces central serotonin (5-HT) activity	Leads to mood dysregulation and “starves” the brain of cognitive energy[5,10]
5-HT1A receptor	Reduced sensitivity in the prefrontal cortex due to thyroid deficiency	Weakens “top-down” inhibition, increasing the likelihood of impulsive actions[7,9]
5-HT2 receptor	Increased sensitivity as a result of low thyroid levels	Strongly linked to the pathogenesis and progression of suicidal behavior[10]
Blunted TSH response	Failure to respond normally to thyrotropin-releasing hormone	Serves as a physiological indicator for higher risk of violent suicide attempts[11]
Hypercortisolemia	High cortisol (HPA axis) inhibits deiodinase enzymes (HPT axis)	Blocks the production of neuroprotective hormones, leading to treatment resistance[5,6]

TSH: Thyroid-stimulating hormone; HPA: Hypothalamic-pituitary-adrenal; HPT: Hypothalamic-pituitary-thyroid.

The critical need for sex-stratified analysis

A critical perspective that merits further attention is the ‘gender paradox’ of suicidal behavior. Globally, women exhibit significantly higher rates of suicide attempts-often linked to higher prevalence of internalizing disorders and thyroid dysfunction-whereas men present higher rates of suicide mortality, frequently associated with more violent methods and lower help-seeking behavior.

Hypothyroidism and subclinical hypothyroidism exhibit a higher prevalence among women compared to men, often attributable to elevated rates of autoimmune sensitivity. In the context of MDD, women frequently present with different clinical phenotypes, including higher rates of somatic symptoms and “atypical” features such as hypersomnia and weight gain-symptoms that overlap significantly with hypothyroid states[12]. The physiological implications of a TSH level of 5.43 μIU/mL may vary significantly between sexes (Figure 2). In women, estrogen has been observed to increase T4-binding globulin, which may consequently alter the “set point” of TSH feedback. Furthermore, the higher prevalence of TPOAb in women suggests that their hypothalamic-pituitary-gonadal axis may be more prone to volatile fluctuations during a depressive episode. It is important to note that women are also statistically more likely to attempt suicide. Therefore, the TSH inflection point identified by Deng et al[1] may actually be lower or more aggressive in female cohorts. Future data analysis should prioritize sex-stratified models to determine if clinical intervention thresholds should be adjusted based on biological sex.

Figure 2 Conceptual dose-response relationship between thyroid-stimulating hormone and suicide. This graph visualizes the key finding by Deng et al[1], identifying a nonlinear, threshold-based association. Below the critical inflection point of 5.43 µIU/mL, the risk curve remains relatively stable. Once thyroid-stimulating hormone crosses this threshold into the mildly pathologically elevated range, the risk of suicide attempts increases sharply (indicated by the orange upward arrow). This diagram highlights the clinical significance of 5.43 μIU/mL as a primary biological “red flag” and underscores the need for sex-stratified risk models. TSH: Thyroid-stimulating hormone.

Integration of clinical implications and the metabolic-thyroid-suicide nexus

The integration of HPT axis markers into routine psychiatric assessment offers a vital opportunity to bridge the gap between subjective symptom reporting and objective biological risk. While Deng et al[1] adjusted for metabolic variables such as total cholesterol, triglycerides, and fasting blood glucose, these markers should not be viewed merely as “confounders”; they are physiologically downstream of thyroid function. As the primary regulators of systemic metabolism, thyroid hormones exert a profound influence on these indices. Specifically, hypothyroidism-indicated by elevated TSH levels-frequently results in hypercholesterolemia and altered glucose sensitivity[13]. A clinical screening protocol prioritizing the detection of “local” brain hypothyroidism, even when peripheral free thyroxine appears normal, could identify patients with diminished neurochemical resilience before they reach a state of metabolic crisis.

A substantial body of research has identified a correlation between low cholesterol levels and glucose dysregulation with increased impulsivity and suicide risk[14], giving rise to a complex “metabolic-endocrine” network. This network operates through an Endocrine Pathway, where elevated TSH directly alters neuroplasticity and mood-regulating circuits[15], and a Metabolic Pathway, where TSH-induced changes in lipids and glucose create a pro-inflammatory environment that compromises brain health[16]. Specifically, monitoring the T3/T4 ratio and TSH response patterns can serve as an early warning system for impaired top-down inhibition and treatment resistance. By integrating thyroid function with metabolic blood tests, clinicians can establish a more holistic “biosignature” of suicide risk. For instance, a patient presenting with both elevated TSH and abnormal lipid profiles may represent a high-risk “metabolic-depressive” subtype requiring more aggressive clinical monitoring and the potential use of adjunct therapies to restore cerebral energy metabolism and stabilize the serotonergic system, ultimately lowering the threshold for impulsive suicidal behavior and improving long-term functional outcomes.

Limitations and future perspectives

While this commentary highlights critical neurobiological nuances, it is not without limitations. Primarily, our analysis relies on existing literature and does not provide new empirical data to validate the proposed sex-stratified thresholds. Furthermore, we have not fully explored how inter-ethnic differences in iodine intake and genetic susceptibility to thyroiditis might shift TSH baselines globally.

To address these gaps, future research must transition from cross-sectional observations to longitudinal tracking. It is imperative to determine whether TSH levels fluctuate in tandem with the severity of suicidal ideation or if the 5.43 μIU/mL threshold signifies a stable, trait-like vulnerability. Moreover, multi-omic research integrating TSH data with functional neuroimaging could elucidate the clinical significance of the identified inflection point by mapping it against functional connectivity within the “suicide circuit”-specifically between the prefrontal cortex and the anterior cingulate[17].

There is also a pressing need for clinical trials investigating whether treating subclinical hypothyroidism can directly reduce suicidal ideation in FEDN-MDD patients. Such studies should adopt a more comprehensive framework that incorporates environmental factors, including dietary iodine and childhood trauma, both of which exert significant influence on the HPT axis and MDD risk[18]. Ultimately, these efforts could unveil novel pharmacological pathways for suicide prevention, transforming a public health concern into a manageable clinical target.

CONCLUSION

In conclusion, while Deng et al[1] established a vital benchmark, our integration of the metabolic-thyroid-suicide nexus suggests that TSH is a dynamic component of a broader ‘biosignature’ of risk. By transitioning to sex-sensitive thresholds and recognizing the metabolic pathways downstream of HPT dysfunction, clinicians can transform TSH from a static lab value into a proactive tool for preventing the transition from suicidal ideation to action.